"Genes, p53" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
| Descriptor ID |
D016158
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.385 G05.360.340.024.340.415.400.385
|
| Concept/Terms |
Genes, p53- Genes, p53
- TP53 Genes
- Genes, TP53
- Gene, TP53
- TP53 Gene
- p53 Genes
- Gene, p53
- p53 Gene
|
Below are MeSH descriptors whose meaning is more general than "Genes, p53".
Below are MeSH descriptors whose meaning is more specific than "Genes, p53".
This graph shows the total number of publications written about "Genes, p53" by people in this website by year, and whether "Genes, p53" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, p53" by people in Profiles.
-
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
-
Paired tumor sequencing and germline testing in breast cancer management: An experience of a single academic center. Cancer Rep (Hoboken). 2020 12; 3(6):e1287.
-
Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic TP53 Mutation. J Natl Compr Canc Netw. 2018 05; 16(5):461-466.
-
Aurora Kinase A is critical for the Nkx6.1 mediated ?-cell proliferation pathway. Islets. 2015; 7(1):e1027854.
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
-
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8.
-
Transitions at CpG dinucleotides, geographic clustering of TP53 mutations and food availability patterns in colorectal cancer. PLoS One. 2009 Aug 31; 4(8):e6824.
-
MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001 Nov 30; 276(48):45255-60.
-
The early detection of occult lung cancer. Chest Surg Clin N Am. 2000 Nov; 10(4):737-49.
-
Regulators of proliferation and apoptosis in carcinoma of the larynx. Laryngoscope. 1998 May; 108(5):630-8.